Company: CSTL
Filing Date: 2025-03-28
Form Type: PRE 14A
Source: 0001447362-25-000050
Chunk: 77

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-03-28
Form: PRE 14A
Chunk 77
---
 of March 13, 2019, which were fully vested upon issuance, each option award vests as follows: 25% of the shares subject to the option vest on the first anniversary of the vesting commencement date, and the balance of the shares vest in equal monthly installments thereafter over the next 36 months, provided in each case that the holder is then providing services to us in accordance with the terms of the 2008 Plan, the 2018 Plan or the 2019 Plan, as applicable. Certain option awards are subject to acceleration of vesting, as described under “—Potential Benefits upon Termination or Change-in-Control.”

(3) Unless otherwise indicated, all of the option awards were granted with a per share exercise price equal to the fair market value of one share of our common stock on the date of grant. Prior to the IPO, the fair market value of our common stock was determined in good faith by our board of directors. Following the IPO, the fair market value of our common stock is the closing selling price per share of our common stock as reported on the Nasdaq on the date of grant or other relevant determination date.

(4) This column consists of time-based RSUs, which vest in four equal annual installments beginning on the first anniversary of the vesting commencement date, except for performance-based RSUs granted on December 23, 2022, this column reflects the portion of the performance-based RSUs that vest on August 8, 2025, one year following the achievement of the 2022 PSUs Revenue Goal.

(5) Calculated using a price of $26.65 per share, which was the closing price of our common stock as reported on the Nasdaq on December 31, 2024, the last trading day of 2024. With respect to the performance-based RSUs discussed in footnote (6), the amounts shown in this column reflect the single payout scenario for the awards.

(6) This column consists of performance-based RSUs granted in March 2024, which vest based on the achievement of the successful launch of a new commercial test, revenue goal and achieving positive EBITDA. If the successful launch of a new commercial test is achieved, revenue goal is achieved and positive EBITDA is achieved, then 50%, 25% and 25%, respectively, of the performance-based RSUs will vest. The PSUs provide for a single payout scenario, which is used as the basis for the presentation of the PSUs in the table